Evidence map›Paper›PMID 28525973›Full record

ArticleBMC infectious diseases2017

Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.

Miriam Wiese-Posselt, Anette Siedler, Annette Mankertz, Andreas Sauerbrei, Hartmut Hengel, Ole Wichmann, Christina Poethko-Müller

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Observational
  12. Herpesvirus-Associated Encephalitis: an Update.Current tropical medicine reports · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Miriam Wiese-PosseltDepartment for Infectious Disease Epidemiology, Robert Koch Institute, Immunization Unit, Seestrasse 10, 13353, Berlin, Germany. Wiese-PosseltM@rki.de.ORCID 0000-0001-9300-2563
Anette SiedlerDepartment for Infectious Disease Epidemiology, Robert Koch Institute, Immunization Unit, Seestrasse 10, 13353, Berlin, Germany.
Annette MankertzDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Andreas SauerbreiInstitute of Virology and Antiviral Therapy, German Consulting Laboratory for HSV and VZV, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.
Hartmut HengelInstitute of Virology, Medical Center, Albrecht-Ludwigs-University, Faculty of Medicine, Freiburg, Germany.
Ole WichmannDepartment for Infectious Disease Epidemiology, Robert Koch Institute, Immunization Unit, Seestrasse 10, 13353, Berlin, Germany.
Christina Poethko-MüllerDepartment of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.
Robert Koch Institute · DEJena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella vaccine era in Germany, to identify factors associated with VZV seropositivity, and to assess the suitability of a commercially available ELISA for VZV seroepidemiological studies by comparing it with an in-house fluorescent antibody to membrane antigen test (FAMA) as the gold standard.

methodsSerum samples of 13,433 children and adolescents aged 1-17 years included in the population-based German Health Interview and Examination Survey for Children and Adolescents (KiGGS; conducted 2003-2006) were tested for anti-VZV IgG by ELISA. All samples with equivocal ELISA results and a random selection of ELISA-negative and -positive samples were tested by FAMA. Statistical analyses were conducted using a weighting factor adjusting the study population to the total population in Germany. Seroprevalences were calculated as percentages (%) with a 95% confidence interval (CI). Odds ratios (OR) were computed by multivariate logistic regression to determine the association between socio-demographic factors and VZV seropositivity.

resultsThe VZV seropositivity rate was 80.3% (95% CI: 79.3-81.3) in varicella-unvaccinated children and adolescents. VZV seropositivity rates differed significantly between age groups up to age 6 years, but not by gender. Of 118 retested serum samples with an equivocal ELISA result, 45.8% were FAMA-positive. The proportion of samples tested as false-negative in by ELISA varied by age group: 2.6% in children aged 1-6 and 9% in children aged 7-17 years. Multivariate analyses showed that age, having older siblings, and early daycare start were associated with seropositivity in preschoolers; migration background reduced the chance of VZV seropositivity in schoolchildren (OR: 0.65; 0.43-0.99) and adolescents (OR: 0.62; 0.4-0.97).

conclusionIn the pre-varicella vaccine era, most children in Germany contracted varicella by age six. Schoolchildren with a migration background and children without siblings have an increased risk of being VZV seronegative and should be targeted for catch-up vaccination, if they have no history of chickenpox. ELISAs are suitable for use in population-level serosurveys on VZV, but samples with equivocal ELISA results should be retested by FAMA.

Indexed as

Seroepidemiologic StudiesAdolescentAntibodies, Anti-IdiotypicAntibodies, ViralAntigens, ViralChickenpoxChickenpox VaccineChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleGermanyHerpesvirus 3, HumanHumansInfantLogistic ModelsAntibodies, Anti-IdiotypicAntibodies, ViralAntigens, Viralanti-IgGChickenpox VaccineElisaFAMASeroprevalenceVaricella vaccinationVaricella-zoster virus

Identifiers

PMID28525973
PMCPMC5438501
OpenAlexW2616793517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.